Novartis AG
Novartis AG is a Switzerland-based medicines company that discovers, develops, manufactures, and commercializes prescription therapies across a broad range of therapeutic areas. Its business is organized around innovative branded pharmaceuticals and a portfolio of established medicines sold through global healthcare channels.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueBranded prescription drugs for chronic, rare, and specialty diseases.
Therapies for autoimmune and inflammatory conditions such as Cosentyx and Xolair.
Medicines for neurological and neuromuscular disorders, including Kesimpta and Zolgensma.
Cancer therapies and targeted treatments for hematology and solid tumors.
Drugs for cardiovascular and metabolic diseases, including several mature brands.
Customers
Novartis sells primarily to healthcare providers, hospitals, specialty clinics, and pharmacies that dispense prescription medicines to patients. It also serves governments, payers, and other reimbursement systems that influence access and pricing for branded therapies. Demand is driven by disease prevalence, clinical adoption, reimbursement coverage, and the launch cycle of new medicines.
Hospitals, specialists, and clinics prescribing Novartis therapies for specific diseases.
National health systems and insurers that determine reimbursement and access terms.
Channel partners that dispense and distribute prescription medicines to patients.
End users of Novartis medicines, especially in chronic and specialty indications.
Strategy
Novartis focuses on building its pipeline and advancing selected late-stage compounds while defending and extending key branded products. The company also emphasizes lifecycle management, external business opportunities, and technology-enabled development to strengthen its long-term medicines portfolio. Its strategy is tied to sustaining innovation in areas with high unmet medical need and durable reimbursement support.
New approvals replace lost exclusivity and sustain the branded medicines franchise.
Extensions and new indications can preserve demand for major products.
Acquisitions and collaborations can add platform technologies and assets.
IT, data, and AI investments support research productivity and commercialization.
Geography
Novartis operates globally, with product sales and clinical activity spanning the Americas, Europe, Asia-Pacific, and other international markets. The company’s exposure is shaped by national reimbursement systems, patent regimes, and currency movements, while manufacturing and supply chains support a worldwide branded-drug franchise. The excerpts provided do not include an authoritative revenue-by-country table, so the profile reflects the company’s global operating footprint rather than a country map.
Risks
Novartis faces the standard pharmaceutical risks of patent expiry, pricing pressure, clinical trial setbacks, and regulatory scrutiny, all of which can disrupt product demand and pipeline value. The report also highlights operational and geopolitical exposures, including tariffs, war-related disruption, foreign exchange swings, cybersecurity, and manufacturing quality issues. Because the business depends on a small number of key medicines and global reimbursement systems, these risks can affect revenue durability and launch timing.
- Loss of patent protection and exclusivityImpact: HighLikelihood: High
Novartis relies on branded medicines that face generic or biosimilar competition over time.
Exposure: Key products and established brands
- Healthcare pricing and reimbursement pressureImpact: HighLikelihood: High
Governments and payers can force lower prices, stricter access, or transparency requirements.
Exposure: Global branded medicines portfolio
- Clinical development and regulatory riskImpact: HighLikelihood: Medium
Pipeline candidates depend on trial success, approvals, and post-approval oversight.
Exposure: Late-stage development compounds
- Manufacturing and quality issuesImpact: HighLikelihood: Medium
Pharmaceutical production must meet strict standards, and failures can delay supply or trigger remediation.
Exposure: Drug manufacturing and distribution
- Foreign exchange and geopolitical disruptionImpact: MediumLikelihood: High
Global operations create exposure to currency movements, tariffs, and regional conflict.
Exposure: International sales and supply chain
Accounting
Judgemental itemsIncome statement and cash flow presentation will change without affecting net income.
Impact: Reclassification of foreign exchange, interest, dividends, and cash flow line items
Acquisitions require fair value measurement of acquired assets and liabilities.
Impact: Purchase price allocation, amortization, and potential goodwill
Pharma revenue depends on estimates for rebates, discounts, returns, and chargebacks.
Impact: Net sales timing and amount
Drug assets can lose value if product demand, exclusivity, or pipeline assumptions weaken.
Impact: Earnings volatility and balance sheet write-down risk
Similar listed companies
Publicly listed companies with a comparable business focus.
AstraZeneca PLC
AZN · Pharmaceutical Preparations
AstraZeneca PLC is a global biopharmaceutical company focused on discovering, developing, and commercialising prescription medicines.
Novo Nordisk A/S
NVO · Pharmaceutical Preparations
Novo Nordisk A/S is a Denmark-based pharmaceutical company focused on medicines for diabetes, obesity, and other serious chronic diseases.
NovaBridge Biosciences
NBP · Pharmaceutical Preparations
NovaBridge Biosciences is a global biotechnology company focused on discovering, developing, and partnering around differentiated therapeutic candidates in oncology and ophthalmology.
Sanofi
SNY · Pharmaceutical Preparations
Sanofi is a biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines and vaccines.
Pfizer, Inc
PFE · Pharmaceutical Preparations
Viatris Inc
VTRS · Pharmaceutical Preparations
Last updated: 28/09/2026